Clinical Trial: A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07472491) titled 'A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients' on Feb. 12.

Brief Summary: This is an operationally combined Phase 2/3 study, which will be conducted and evaluated in 2 distinct parts:

* Phase 2: Prospective, adaptive, multicenter, non-randomized, single-blind, dose-finding, including participants with known or highly suspected lesions of the CNS. The aim of the Phase 2 part is to identify an optimized dose of mangaciclanol for the Phase 3 part of the study.

* Phase 3: Prospective, multicenter, randomized, controlled, single-blind, cross-over, including par...